A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes

This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes. The study will evaluate the safety, local tolerability, and pharmacokinetic profile of two concentrations of ZYG24004 (1% and 3%) after topical administration once or twice (once weekly for two consecutive weeks), and will explore preliminary efficacy.

NCT Number	NCT07668999
Lead Sponsor	Sinomune Pharmaceutical Co., Ltd
Conditions	Tinea Pedis
Enrollment	64 participants
Start Date	2026-07-21
Primary Completion	2027-06-10 (estimated)
Study Completion	2027-06-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-04